Secretory leukocyte protease inhibitor in ovarian endometriomas following GnRH agonist therapy

Obstetrics and Gynecology

Volumn 97, Issue 4, 2001, Pages 561-566

  Suzumori, Nobuhiro ^a,b,c   Sato, Makoto ^a,b,c   Ikuta, Katsuo ^a,b,c   Suzumori, Kaoru ^a,b,c  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; MESSENGER RNA; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; CYSTADENOMA; ENDOMETRIOSIS; ENDOMETRIUM TUMOR; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NORTHERN BLOTTING; OVARY TUMOR; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; ASCITIC FLUID; BLOTTING, NORTHERN; CASE-CONTROL STUDIES; ENDOMETRIOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUPROLIDE; MIDDLE AGED; OVARIAN DISEASES; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS;

EID: 0035083368     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(00)01200-X     Document Type: Article

References (21)

1. Expression of secretory leukocyte protease inhibitor in women with endometriosis
2. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase
3. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
4. Antiproteases
5. Expression of the secretory leukoprotease inhibitor gene in epithelial cells
6. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide
7. Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycles
8. Pathogenesis of endometriosis
9. Management of endometriosis with gonadotropin-releasing hormone agonists
10. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities
11. Large ovarian endometriomas
12. Tissue inhibitor of metalloproteinase-1 concentrations are attenuated in peritoneal fluid and sera of women with endometriosis and restored in sera by gonadotropin-releasing hormone agonist therapy
13. Coexpression of cytokeratin and vimentin in eutopic endometrium and endometriosis throughout the menstrual cycle: Evaluation by a computerized method
14. Estrogen receptor analysis: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies
15. 2 on the human cervix: Stimulation of interleukin 8 and inhibition of secretory leukocyte protease inhibitor
16. Cell surface-bound elastase and caathepsin G on human neutrophils: A novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases
17. Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases, and their inhibitors in rat models for adhesion formation and endometriosis: Potential GnRH-a-regulated mechanisms reducing adhesion formation
18. Ovarian endometrial cyst: The role of gonadotropin-releasing hormone agonist and/or drainage
19. Immunomodulation in women with endometriosis receiving GnRH agonist
20. Paracrine changes in the peritoneal environment of women with endometriosis
21. Binding of human secretory leukocyte protease inhibitor in uterine cervical mucus to immunoglobulins: Pathophysiology in immunologic infertility and local immune defense